002737 葵花药业
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入843,91927.19%2,317,9593,377,0485,700,2875,094,511
减:营业总成本690,47212.76%2,580,3952,865,4374,496,1214,055,840
    其中:营业成本368,490-11.44%1,433,6091,860,9752,491,5592,152,457
               财务费用74-105.66%(3,988)(23,099)(31,963)(11,157)
               资产减值损失(17,984)1,473.43%(83,666)(56,930)(978)(29,358)
公允价值变动收益(8,710)2,399.29%3,892(12,985)(16,388)(19,307)
投资收益9,412223.97%31,04924,93246,9649,390
    其中:对联营企业和合营企业的投资收益685-263.52%(364)(2,225)(2,506)(1,332)
营业利润140,18492.81%(251,189)636,2431,366,8261,084,990
利润总额141,487101.58%(271,155)634,4881,354,7701,081,105
减:所得税费用25,695126.46%25,919131,756189,831171,370
净利润115,79296.79%(297,073)502,7321,164,939909,735
减:非控股权益5,506218.36%(39,246)10,68645,79742,513
股东净利润110,28693.11%(257,828)492,0451,119,142867,222

市场价值指针
每股收益 (元) *0.19090.00%-0.4400.8401.9201.480
每股派息 (元) *----0.2000.5001.5001.000
每股净资产 (元) *6.761-10.99%6.5727.4998.1577.200
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容